Banco Santander SA vs TransMedics Group Inc — how do they compare? Banco Santander SA trades at $13.7 (market cap $191.46B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Banco Santander SA is far larger — about 75.4× TransMedics Group Inc's market cap, and Banco Santander SA pays a 2.09% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SAN | TMDX | |
|---|---|---|
Market Cap | $191.46B | $2.54B |
Sector | Financials | Technology |
52-Week High | $14.37 | $150.42 |
52-Week Low | $8.40 | $61.99 |
Dividend Yield | 2.09% | — |
Enterprise Value | — | $2.94B |
Signals from Pluang's Aura AI — not financial advice
Santander (SAN) trades at $13.65, up 0.74% with mixed technical signals showing bearish moving averages but oversold RSI. The company reported Q1 2026 EPS beat ($0.41 vs $0.29 expected) and maintains strong profitability with 26.72% net margin and 16.18% ROE. Recent developments include the $12.2 billion Webster Bank acquisition and AI-driven cost initiatives targeting $1.15 billion in business value.
SAN offers value with a 13.23 P/E and dividend yield near 4.4%, supported by 64% analyst buy ratings. Key risks include declining cash flows (-$28.13B in 2024) and Spanish antitrust probes. The stock's upside depends on successful integration of acquisitions and AI efficiency gains offsetting macroeconomic pressures on European banking.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →